Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells

被引:63
作者
Angeloni, SV
Martin, MB
Garcia-Morales, P
Castro-Galache, MD
Ferragut, JA
Saceda, M [1 ]
机构
[1] Univ Miguel Hernandez, Ctr Biol Mol & Celular, Inst Biol Mol & Celular, Alicante 03202, Spain
[2] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA
[3] Georgetown Univ, Dept Oncol, Washington, DC 20007 USA
[4] Georgetown Univ, Dept Biochem, Washington, DC 20007 USA
[5] Georgetown Univ, Dept Mol Biol, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA
[6] Hosp Gen Univ Elche, Alicante 03202, Spain
关键词
D O I
10.1677/joe.0.1800497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The results presented here demonstrate that p53 upregulates estrogen receptor-alpha (ERalpha) expression in the human breast cancer cell line MCF-7. Two approaches were used to alter the activity of p53 in the cells. In the first approach, stable transfectants expressing an antisense p53 were established. In the stable clones, expression of antisense p53 resulted in a decrease in the expression of ERalpha protein. In the second approach, MCF-7 cells were transiently transfected with wild-type p53. Overexpression of p53 increased the amount of ERalpha. To determine whether the effects of p53 on the expression ERalpha were due to changes in transcription, deletion mutants of the ERalpha promoter were used. This experimental approach demonstrated that p53 up-regulates ERalpha gene expression by increasing transcription of the gene through elements located upstream of promoter A. Transfection assays using p53 mutants further demonstrated that the p53-induced increase in ERalpha gene transcription was not dependent on the ability of p53 to bind to DNA but on its ability to interact with other proteins.
引用
收藏
页码:497 / 504
页数:8
相关论文
共 30 条
[21]   REGULATION OF THE ESTROGEN-RECEPTOR IN MCF-7 CELLS BY ESTRADIOL [J].
SACEDA, M ;
LIPPMAN, ME ;
CHAMBON, P ;
LINDSEY, RL ;
PONGLIKITMONGKOL, M ;
PUENTE, M ;
MARTIN, MB .
MOLECULAR ENDOCRINOLOGY, 1988, 2 (12) :1157-1162
[22]  
Sirvent JJ, 2001, HISTOL HISTOPATHOL, V16, P99, DOI 10.14670/HH-16.99
[23]   Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions [J].
Smith, PD ;
Crossland, S ;
Parker, G ;
Osin, P ;
Brooks, L ;
Waller, J ;
Philp, E ;
Crompton, MR ;
Gusterson, BA ;
Allday, MJ ;
Crook, T .
ONCOGENE, 1999, 18 (15) :2451-2459
[24]  
Stoica A, 1999, J CELL BIOCHEM, V75, P640, DOI 10.1002/(SICI)1097-4644(19991215)75:4<640::AID-JCB10>3.0.CO
[25]  
2-8
[26]  
TISHLER RB, 1995, CANCER RES, V55, P6021
[27]  
Velculescu VE, 1996, CLIN CHEM, V42, P858
[28]   Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches [J].
Wang, LQ ;
Wu, Q ;
Qiu, P ;
Mirza, A ;
McGuirk, M ;
Kirschmeier, P ;
Greene, JR ;
Wang, YL ;
Pickett, CB ;
Liu, SX .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (47) :43604-43610
[29]  
YonishRouach E, 1995, ONCOGENE, V11, P2197
[30]   INDUCTION OF CELLULAR P53 ACTIVITY BY DNA-DAMAGING AGENTS AND GROWTH ARREST [J].
ZHAN, QM ;
CARRIER, F ;
FORNACE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) :4242-4250